Annual Clinical Contract Evaluations: Are You Ready?


AHRMM Webinar Image


Price: Member: FREE  |  Non-Member: $99.00

CEC Hours: 1

Order Webinar



The process of annual clinical contract evaluations can be time consuming and overwhelming, and supply chain has a unique opportunity to support the continuum of care as we expand our CQO efforts and strive to meet requirements. In this webinar, we discuss the clinical contract evaluation process, including government requirements, expectations, and improving contract performance with the use of key performance indicators.

Attendees will hear firsthand what the Dana-Farber Cancer Institute (DFCI) learned during their last Joint Commission inspection regarding the evaluation process and the effectiveness of their contracts. In addition, DFCI will share how their annual clinical contract evaluation process has matured through the improvement of existing contract management technology and the automation of the evaluation process.


Learning Objectives:
  • Characterize a clinical contract.
  • Explain the annual clinical contract evaluation requirements.
  • Define key performance indicators.


  • Sarah Buck — Supply Chain Business Analyst, Dana-Farber Cancer Institute
  • Susan Wills — Director Strategic Sourcing and Contracts, Dana-Farber Cancer Institute


Related Resources

On-Demand Educational Webinars
This on-demand session was presented at the Spring Summit: Transformational Excellence.
Hospitals continue to face challenges with their supply chains and are spending more time than ever trying to manage those supply chains. Hospitals,…
Effectively managing a hospital’s inventory has always been important. However, it has become even more important over the past several years. Read…
This white paper explores the importance of balancing health care supply sourcing through both domestic and international suppliers, the benefits and…
Read this article and discover three issues hospitals are focusing on to overcome supply chain challenges in 2023.
Explore common indirect spend risk considerations and prepare to take steps to introduce resiliency within indirect spend categories.